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INTRODUCTION
 The  most  common  and  distressing  symptoms  which  follow 
anaesthesia  and  surgery  are  pain  and  emesis.  Sometimes  nausea  and 
vomiting may be more distressing especially  after  minor  and ambulatory 
surgeries,delaying  the  hospital  discharge.  It  may  be  a  major  factor  in 
upsetting the intra-operative period and post-operative convalescence.
          It is common after spinal anaesthesia for caesarean section with 
reported incidence as high as 66%. Available large number of agents which 
prevent  emesis  indicate  the  magnitude  of  the  problems  and  lack  of 
satisfactory results.
        Nausea and vomiting has been associated for many years in use of 
general  anaesthesia  (i.e.)ether  and  chloroform.  Extensive  description  of 
postoperative nausea and vomiting has been given by Sir John Snow in 1948 
within 18 months of chloroform introduction.
       In pregnancy, there is always an increased frequency of nausea and 
vomiting due  to  various  factors.  When these  are  added to  the  effects  of 
sympathetic  block  in  spinal  anaesthesia,  may  increase  the  frequency  of 
nausea  and  vomiting  in  the  post-operative  period  starting  from  intra-
operative period.
      One of the major factors in this regard is visceral pain and pain resulting 
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from traction  of  peritoneum.  The  present  study  is  done  to  compare  the 
effectiveness of adding fentanyl and midazolam with Bupivacaine and saline 
added with bupivacaine in preventing the incidence of intra-operative and 
post-operative  nausea  and  vomitingThis  study  is  undertaken  with  utmost 
care and the results are discussed.
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AIM OF THE STUDY
               To compare the efficacy of  fentanyl  and midazolam co-
administered  with  bupivacaine  in  reducing  the  incidence  of  nausea  and 
vomiting during caesarean section under spinal anaesthesia.
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HISTORICAL ASPECTS IN POSTOPERATIVE NAUSEA AND
                VOMITING
During  ether  era,  reported  incidence  of  post  operative  nausea  and 
vomiting was as high as 75-80%. Various techniques including olive oil and 
glucose insulin injection were reported to be effective as reported by Robert 
Ferguson in 1912. The effect of atropine was appreciated by Brown Sequard 
as early as 1883.
In  the  second  half  of  the  century  the  incidence  of  post  operative 
nausea and vomiting decreased to about 50%due to the use of non opoid, 
non-ether, regional anaesthetic techniques, refinement of surgical techniques 
and identification  of  patient’s  protective  emetogenic  factors.  There are  3 
kinds of vomiting, the first  of which is attributed to anaesthetics such as 
ether, second due to the reflex responses, third due to the medication used 
intraoperatively.  Subsequent  investigation  unfolded  a  spectrum  of  non- 
anaesthetic  factors  in  the  pathogenesis  of  post  operative  nausea  and 
vomiting.
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Over years numerous drugs have been used in the management of post 
operative nausea and vomiting. Phenothiazines were synthesized in late 19th 
century by chemists in dyeing industry. Promethazine was found in 1930 to 
have good anti-emetic property. However sedative action of it,  limited its 
use. Phenothiazine derivatives have been exclusively used in the treatment 
of post operative nausea and vomiting.
          
The recent introduction of the 5HT3 antagonists such as ondansetron 
and granisetron have reached good heights in the treatment of nausea and 
vomiting.
          There  are  new  antiemetics  like  neurokinin-1,  (substance-P 
antagonists)in development.
          The reason for the magnitude of the problem of PONV persisting 
inspite of the various drug in use can be assessed by four factors.
1. Complexity of the problem:  The variables are that it  becomes 
difficult  to  assess  the  effects  of  an  intervention  as  it  requires 
considerable number of patients of well controlled trials.
2. Inadequate qualification of phenomena:  The phenomenon has 
been poorly qualified i.e.nausea, vomiting, retching etc.
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3. Inadequate antiemetic  regimen:  Unable to identify a good drug 
which can prevent nausea and vomiting.
4. Animal  Model:  A lack  of  model  to  study the physiology and 
pharmacology of mechanism of PONV. Though monkey and dogs 
are available they don’t suffer from pregnancy induced vomiting 
and motion sickness and post operative and post anesthetic emesis.
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HISTORY
SUB ARACHNOID BLOCK:
The  first  neuraxial  block  was  performed  by  James  Leonard 
Corning,  who also  coined  the  term  “Spinal  anesthesia”  on  October  12, 
1865. He injected cocaine 120mg between T11 and T12 spinous process, 
and  obtained  loss  of  sensation  due  to  epidural  block  rather  than  a 
subarachnoid block.
Further  advances took place in Keil,  Germany where August 
Bier and his assistant August Hilderbrant used Quinke’s method to enter the 
intrathecal  space  and  injected  5-15mg  of  cocaine  to  produce  spinal 
anesthesia. This happened on August 16, 1898.
This  was followed by successful  and enthusiastic  practice  of 
spinal anesthesia by others:
• J.B Selclowitsch of St.Petersburg on May11, 1899
• Theodre  Juffier  in  France  on November  9,  1899 
and
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• Rudolph Mates in New Orleans in November 10, 
1899.
Barker  advised  meticulous  sterile  technique  and  introduced  hyperbaric 
solutions.
Serious  complications  from  spinal  anesthesia  were  soon  observed.  In 
1900,F.Gumprecht  observed  15  cases  of  sudden  death  from  lumbar 
puncture.
LOCAL ANAESTHETICS:
1855     :      Friedrich Gaedicke of Germany isolated the first local    
                  anaesthetic agent cocaine.
1860 :       Albert  Neimann  purified  and  named  the  alkaloid  as 
cocaine.
            1884 :   Carl Koller an opthalmalogist from Vienna demonstrated the 
analgesic properties of cocaine on the cornea.William Halstead 
recognized  the  ability  of  injected  cocaine  to  interrupt  nerve 
impulse conduction,  leading to  the introduction of  peripheral 
nerve block anaesthesia and spinal anaesthesia.
1885 : J.L.Corning produced analgesia by neuraxial injection of 
cocaine.
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1904 : Ernest Foureau Synthesized stovaine.
1905 : Einhorn introduced the first synthetic local anaestheic,
procaine.
1943 : Lofgren synthesized the first amide local anaesthetic,
lidocaine.
1947 : Torsten Gordh made the first clinical use of lidocaine.
1957 : Ekenston et al of Sweden synthesized bupivacaine.
1963 : L.J.Tulivuo first used bupivacaine, clinically.
OPIOIDS:
1803 : Morphine was isolated from opium by Serturner.
1832 : Codeine was isolated.
1848 : Papavarine was introduced.
1939 : Meperidine  was  synthesized  and  it  was  used  for 
anaesthesia 
                                   with nitrous oxide.
1942 : Nalorphine a mixed agonist- antagonist was introducecd.
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BENZODIAZEPINES: 
Benzodiazepines  were  discovered  to  be  effective  sedative  and 
hypnotic drugs.
1955 : Sternbach synthesized chlordiazepoxide.
1959 : Sternbach synthesized diazepam.
1961 : Oxazepam, a metabolite of diazepam was synthesized by 
Bell.
             1971 : Lorazepam  was  introduced.  It  was  the  first 
clinically 
                                   used water soluble benzodiazepine.
1977 : Specific receptor for benzodiazepines was identified.
Midazolam was the first benzodiazepine that was produced primarily for use 
in anaesthesia.
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ANATOMY OF SUBARACHNOID SPACE
Subarachnoid local anaesthetics effect their sensory block at the spinal 
cord, which is continuous cephalad with the brain stem via foramen magnum 
and  terminates  distally  in  the  conus  medullaris.  The  distal  termination, 
because of differential growth rates between bony vertebral canal and central 
nervous system, varies from L3 in the infant to L1 in the adult.
Surrounding the spinal  cord in  the bony vertebal  column are  three 
membranes (from within to periphery) : the piamater, arachnoid mater and 
duramater.  The  piamater  is  a  highly  vascularised  membrane  that  closely 
invests  the  spinal  cord.  The  arachnoid  mater  is  a  delicate  non  vascular 
membrane closely attatched to the outermost layer, the duramater. Between 
these two innermost layers is the space called as subarachnoid space. In this 
space  are  the  CSF,  spinal  nerves,  a  trabecular  network  between  two 
membranes,  blood  vessels  that  supply  the  spinal  cord  and  the  lateral 
extensions of the piamater and the dentate ligaments, which provide lateral 
support from the cord to the duramater.
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Although the spinal cord ends at L1, the subarachoid space continues 
to  S2.  The  third  and  the  outermost  layer  in  the  spinal  cord  is  the 
longitudinally organized fibroelastic membrane, the duramater. This layer is 
the direct extension of the cranial dura and extends as spinal dura from the 
foramen magnum to S2 where the filum terminale blends with the coccyx.
THE ANATOMY OF AREAS INVOVED IN CONTROL OF 
VOMITING
There are two areas  which control or take part in the modulation of 
vomiting process. 
i) The vomiting centre
ii) The chemoreceptor trigger zone.
The vomiting centre
The  vomiting  centre  is  located  in  the  reticular  formation  of  the 
medulla oblongata. It takes part in the initiation of vomiting when they are 
stimulated by certain circulating chemical agents.
The chemoreceptor trigger zone
This centre is in or near the area postrema as a ‘V’ shaped tissue in the 
lateral wall of the 4th ventricle near the apex. It’s a circumventricular organ. 
This area is stimulated by radiation sickness, uremia, morphine and other 
emetic agents.
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PHYSIOLOGY OF VOMITING
DEFINITIONS
1.Nausea
It  is  an  unpleasant  sensation  referred  to  as  a  desire  to  vomit,  not 
associated with expulsive muscular movement.
2.Retching
When no stomach contents are expelled even with expulsive muscular 
efforts.
3.Vomiting
It  is  the  forceful  expulsion  of  even  small  amounts  of  upper 
gastrointestinal contents through mouth.
There  are  three  major  components  of  vomiting  reflex,  emetic 
detectors, integrative mechanism and motor output.
The  main  sensors  of  somatic  stimuli  are  located  in  the  gut  and 
chemoreceptor trigger zone.
The emetic stimuli are detected from gut by 2 types of vagal afferent 
fibres.
a) Mechanoreceptor  :  Located  in  muscular  wall  of  the  gut  and  are 
activated by 
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contraction and distension of the gut, on physical damage and manipulation 
during surgery of proximal gut may induce vomiting in over eating.
b) Chemoreceptors: They are situated in the mucosa of upper gut and are 
sensitive to noxious stimuli.
The CTZ (Chemoreceptor Trigger Zone) lies in the area postrema, 
which is able to detect the circulatory toxins in the CSF and activates the 
vomiting  centre  in  the  medulla.  Afferent  impulses  from other  areas  like 
vestibular  labyrinth  ,input  from  limbic  system  and  visual  cortex  can 
stimulate it.The vomiting reflex is divided into two phases.
i) The pre-ejection phase
This is characterized by a sensation of nausea associated with 
cold, 
sweating,  pupil  dilatation,  salivation  and  tachycardia  mediated  by 
sympathetic and para sympathetic nerves.
ii) The ejection phase
This  consists  of  retching  and  vomiting  with  expulsion  of  gastric 
contents.
Causes of vomiting
• Pharyngeal Stimulation
• Gastrointestinal distension
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• Abdominal surgery
• Anaesthetic agents
• Pain
• Opioid medication
• Hypoxia – hypotension
• Hypertension
• Vestibular disturbances
• Psychological factors
• Pregnancy / Hormones
Factors influencing post operative emesis
1. Patient factors
2. Pre operative factors
3. Intra operative factors
a. Anaesthesia factors
b. Anaesthetic techniques
c. Surgical factors
4. Post operative factors
Vestibular cardiac afferents can also stimulate the vomiting centre 
as in 
myocardial infarction.
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The vomiting centre in medulla is  also in close proximity to other 
visceral  centres  like  respiratory  and  vasomotor  centres.  Four  types  of 
receptors are involved in vomiting.
• Cholinergic receptors (M)
• Dopaminergic receptors(D2)
• Histamine receptors(H1)
• Serotonergic receptors(5HT3)
Integrative mechanism
It’s  a  co-ordination  between  many  physiological  systems  and 
autonomic and somatic components of nervous system which occurs in brain 
stem.
The  motor  component  of  vomiting  reflex  is  mediated  by  both 
autonomic and somatic sense, and is coordinated by the vomiting system in 
the brain stem. The vagal neurons that supply the gut and the heart originate 
in  the  dorsal  motor  vagal  nucleus  and  nucleus  ambigus.  The  dorsal  and 
ventral respiratory group which regulate the phrenic nerve output from the 
cervical plexus, are parasympathetic neurons. The output of these nuclei are 
coordinated to produce the physiologic pattern associated with vomiting.
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The vomiting reflex
The act of vomiting is a complex, almost convulsive reflex manoeuver 
involving  both  visceral  and  striated  muscle.  Vomiting  begins  with  deep 
inspiration,  elevation  of  the  soft  palate  to  occlude  the naso  pharynx and 
glottic closure. Then the proximal area of the stomach relaxes and a giant 
contraction of the small intestine forces the previously ingested contents to 
the stomach diluting and buffering the gastric acid. Finally the contraction of 
the  oesophageal  muscles  pull  the  stomach  into  the  thorax  forming  an 
oesophageal funnel and food is forced out of the stomach by contraction of 
the abdominal  muscles  against  the lowered diaphram.  If  glottis  is  closed 
only retching occurs, if the pharynx is relaxed the content is exited through 
the mouth.
Several autonomic signs precede vomiting. The warning signs include 
excessive salivation, dilated pupils, tachypnoea, swallowing, pallor sweating 
and tachycardia.  If  nausea  proceeds  to  retching bradycardia  may  replace 
tachycardia.
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PEPTIDES IMPLICATED IN CAUSING NAUSEA AND VOMITING
Nor-epinephrine
ACTH
Vasopressin Bombesin
Human chorionic gonadotropinThyrotropin releasing hormone
Angiotensin-II Peptide 77
Leu-Enkephalin Neurotensin
Mer. Enkephain Vasoactive intestinal peptide
Cholecystokinin
Insulin
Gastrin
Oxytocin
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PHARMACOLOGIST VIEW OF EMETIC STIMULI
Periphery
  BB
 barrier 
(5HT3, D2, M)     
      Glossopharngeal 
         aff
H1      M  
                 trigeminal
         aff
STOMACH
SMALL INTESINE
(5HT3)
Memory, fear, 
dread, anticipation
HIGHER CENTRESensory Input 
(Pain, Smell, Sight)
AREA POSTREMA
CTZ
EMETIC CENTRE
Medulla
SOLITARY TRACT
NUCLEUS
(5HT3, D2, M1, H1)
CEREBELLUM
Vagal and
sympathetic
afferents
INNER EAR
(motion)
Aminoglycosides Pharnyx
(gagging)
LOCAL 
IRRITANTS
Cytotoxic drugs
CuSO4
Radiation
Bacteria
Viruses
BLOOD BORNE EMETICS
Cytotoxic drugs
Opiods
Cholinomimetics
Digoxin
L-dopa, emetine
Bromocriptine
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FACTORS WHICH LEAD TO INCREASED RISK OF PONV IN 
PREGNANT PATIENTS DURING CAESAREAN SECTION
PATIENT FACTORS
1. There is always increased anxiety, stress and pain when the female 
is coming for caesarean section which itself increases the risk of 
PONV,.
2. The retardation of gastro-intestinal motility 
3. Increased compression of the stomach due to the gravid uterus may 
cause a problem.
4. Decreased lower oesophageal sphincter tone due to the hormone 
progesterone has an increased risk of vomiting.
5. The presence of female hormone oestrogen, progesterone, human 
chorionic  gonadotropin  in  increased  levels,  add  to  the  risk  of 
nausea and vomiting.
6. Anatomical changes in oesophago-gastric junction
7. The addition of any opioids or other analgesics in the labour room 
or ward may in turn increase the risk of nausea and vomiting.
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INTRAOPERATIVE FACTORS
1. Intraoperative  hypotension:  Intra  operative  hypotension  has  a 
greater  influence  in  the  occurence  of  nausea.  When  there  is  a 
greater degree of hypotension,  there is  increased risk of nausea 
&vomiting.
2. Intraoperative O2 supplementation: It has been found out that O2 
supplementation  during   caesarean  section  have  reduced  the 
incidence of PONV.
3. Intraoperative  medications:  Intra  operative  medications  given 
systemically such as prostglandins, methergine have increased the 
incidence of postoperative nausea and vomiting.
4. Surgical factors:
i.  compression of uterus from outside the abdominal cavity 
to deliver the baby , has an increased role to play in the 
riskof nausea and vomiting.
ii. The  manual  delivery  of  placenta  by  compression  of 
uterus  and  pulling  the  umbilical  cord,  is  one  of  the 
important periods, where the patient complains of nausea.
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iii. The exteriorization of the uterus to secure the bleeding 
points and compressing  the uterus to prevent post partum 
hemorrhage,  pull  the  peritoneal  attachments  and  have 
increased   vagal  discharge,  which  is  critical  to  the 
occurence of nausea and vomiting.
POST OPERATIVE FACTORS
i) Anxiety  plays  an  important  role  in  the  post  operative 
period.
ii) The  quick  descent  of  the  local  anaesthetic,and thereby 
patient experiencing pain, may increase the risk of post-
operative nausea and vomiting.
iii) Early ambulation may have an important role to play in 
PONV.
iv) Early oral feeds may also cause increased incidence of 
PONV.
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ADJUVANTS TO LOCAL ANAESTHETICS IN SPINAL 
ANAESTHESIA
Local anesthetic agents have been widely used in spinal anaesthesia. 
One of the main disadvantages is the limited duration of block achieved with 
local anaesthetics. To overcome this, various adjuants have been tried and 
used  successfully.  This  addition  of  adjuant  has  further  expanded  the 
advantage of regional anaesthesia over general anaesthesia.
ADJUANTS:
          These  may  be  opioids  like  morphine,fentanyl,  sufentanil  or 
buprenorphine.  It  may  be  benzodiazepines,  alpha  2  agonist  clonidine, 
acetylcholine  esterase  inhibitors  like  neostigmine,NMDA  receptor 
antagonist ketamine or nonsteroidal anti inflammatory agents.
These adjuants usually confer the advantage of 
• Rapid onset time 
• Differential blockade
• Inhibition of tourniquet pain
• Improved and prolonged duration of post operative analgesia
• Inhibition  of  visceral  pain/pain  associated  with  peritoneal 
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traction.
Also  these  adjuants  decrease  the  amount  of  local  anaesthetic  required  to 
produce  the  same  effect  thereby  reducing  the  risk  of  local  anaesthetic 
toxicity, hypotension and profound motor blockade. 
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OPIOIDS
The term opioids refer  to all  compounds related to opium, derived 
from juice of  opium poppy, papaver  sommniferum. Opiates  are  the term 
used  for  drugs  derived  from  opium.  Morphine  is  the  prototype  opioid. 
Opioid compounds can be classified as naturally occuring,semisynthetic and 
synthetic opioids. With the development of synthetic drugs with morphine 
like effects, the term opioid is now used to refer to all exogenous substances, 
natural  and  synthetic  that  binds  to  opioid  receptors  and  produces  some 
agonisitic effects.
CLASSIFICATION:
Naturally occurring opioids are divided into two chemical classes
1. Phenanthrene-eg. Morphine and codeine
2. Benzylisoquinolines-eg. Papavarine 
Semisynthefic opioids result from relatively simple modification of 
morphine molecule.eg.diacetylmorphine.
Synthetic opioids contain phenanthrene nucleus. They are classified 
into 
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four subdivisions.
1. Morphinan derivative-eg.levorphanol
2. Methadone derivative-eg.methadone
3. Benzomorphan derivatives-eg.pentazocine
4. Phenylpiperidine  derivatives-eg.meperidine,  fentanyl, 
sufentanil,alfentanil
OPIOID   RECEPTORS:
             The  presence    of  opioid   binding    sites  in  the  nervous  system 
was   reported   in  the  year  1973.    Immuno  histochemical     studies  have 
demonstrated   opioid   receptors  in  various  areas  of  the  central  nervous 
system.   These   include  the  amygdala,   the  mesencephalic   reticular 
formation,   the  periaqueductal   gray  matter  and  the  rostral  ventral 
medulla.
          Based on pharmacological  experiments   three   types  of  opioid 
receptors  were  published.
34
       (i)       mu or  µ     for  morphine   type
       (ii)      Kappa or K for Ketocyclazocine type
       (iii)    Sigma or σ for SKF 10047 type
         In addition   two other receptors have been identified  in  vas  deferens 
of  mouse  namely  the delta  ( δ ) and epsilon(Σ) receptors. All the receptors 
bind to a super family guanidine protein coupled receptors.
The µ or morphine preferring receptors are principally responsible for 
supra  spinal  and  spinal  analgesia.  Various  subtypes  have  been  proposed 
based  on  post  translational  modification  of  µ  receptor.  µ1  receptor  is 
speculated  to  produce  analgesia.  While  µ2  receptor  is  responsible  for 
hypotension, bradycardia and respiratory depression. Delta receptors serve 
to modulate the activity of µ receptor. Kappa receptors are those to which 
most  of the opioid agoinst-antagonist  bind. Respiratory depression is less 
common with Kappa receptor activation than µ. Dysphoria and diuresis may 
occur. High intensity painful stimulations are resistant to the analgesic effect 
of Kappa receptor activation.
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CHARACTERISTICS OF OPIOID RECEPTORS
Mu (µ1) Delta (δ) Kappa(K)
1 Endogenous Ligand β-endorphin Leu-enkephalin
Met-enkephalin
Dynorphin
2 Agonist Morphine
Fentany1
DPDPE
Deltorphin
     Buprenorphine 
     Pentazocine
3 Antagonist Naloxone
Naltrexone
Naloxone
Naltrindole
Naloxone
BNI
4 Coupled G Protein Gi/o Gi/o Gi/o
5 Adenylate cyclase Inhibition Inhibition Inhibition
6 Effect Analgesia
Supraspinal and spinal (µ1)
Euphoria(µ1)
Respiratory
Depression(µ2)
Bradycardia (µ2)
Constipation(µ2)
Analgesia
Respiratory
Depression
Constipation
(minimal)
Analgesia
(Spinal)
Dysphoria
Sedation
Miosis 
Diuresis
PHARMACOLOGICAL ACTIONS OF OPIOIDS
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Receptor Action
Agonists 
Antagonists
1 Suprapinal
Spinal
µ,σ,k
µ,σ,k
Analgesic                  No effect
Analgesic                   No 
effect
2 Respiratory
Function
µ Decrease                        No 
effect
3 Gastro intestinal
Tract
µ, k Decrease                   No effect
4 Psychotomimesis k Increase                           No 
effect
5 Feeding µ,σ,k      Increase 
Decrease
6 Sedation µ, k Increase                       No 
effect
7 Diuresis k Increase
8 Hormone
Secretion
(a)Prolactin
(b)Growth
hormone
µ
µ and σ
Increase  release 
Decrease
release
Increase  release 
Decrease
release
37
MECHANISM OF ANALGESIC ACTION:
Opioids  act  as  agonists  at  stereospecific  opioid  receptors  at 
presynaptic and post synaptic sites in the central nervous system and also 
outside central nervous system in peripheral tissues.
MECHANISM OF ACTION IN CENTRAL NERVOUS SYSTEM:
The analgesic  effect  of  opioids  result  from their  ability  to  directly 
inhibit  the  ascending  transmission  of  nociceptive  information  from  the 
spinal cord dorsal horn. It has a descending inhibitory analgesic action by 
activation of pain control circuits that descend from the midbrain via the 
rostral  ventromedial  medulla  (RVM)  to  the  spinal  cord  dorsal  horn.  In 
addition,local spinal  mechanisms also take part  in the analgesic action of 
opioids.
Existence of the opioids in the ionized state is necessary for strong 
binding  at  the  anionic  opioid  receptor  site.  Stereochemically,levorotatory 
forms are found to be most active. The affinity of most opioid agonists for 
receptors correlated with their analgesic property.
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The  principal  effect  of  opioid  receptor  activation  is  a  decrease  in 
neuro transmission. This decrease in neuro transmission is largely due to 
presynaptic  inhibition  of  neurotransmitter  release,  although  post  synaptic 
evoked activity may also occur. 
The  neurotransmitters  whose  releases  are  also  inhibited  include 
acetylcholine, dopamine, norepinephine and substance P.
The intracellular biochemical  events activated by binding of opioid 
agoinst to opioid receptor are:
(i) Increased potassium conductance-leading to hyperpolarization
(ii) Calcium channel inactivation
Both of which produce an immediate decrease in neurotransmitter release.
Opioid receptors mediated inhibition of adenylate cyclase,causing a 
decrease in cellular cAMP has a delayed effect, via a reduction in cAMP 
responsive  neuropeptide  agent  and  a  reduction  in  neuropeptide  mRNA 
concentrations.
MECHANISM OF ACTION IN PERIPHERAL TISSUES:
Opioids are  effective  in  inflammatory  hyperalgesic  conditions.  The 
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opioids  bind to  receptors  in  the  primary  afferent  neurons  and mimic  the 
action of endogenous ligands, resulting in the activation of pain modulating 
(antinociceptive) systems.
EFFECT OF OPIOIDS ON VARIOUS SYSTEMS OF THE BODY:
These  can  be  classified  into  therapeutic  drug  effects  and  non-
therapeutic drug effects.
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THERAPEUTIC DRUG EFFECTS:
OPIOIDS AS ANAESTHETICS:
The  capacity  of  opioids  to  produce  anesthesia  is  debated.  General 
anaesthesia  can  be  considered  in  terms  of  its  component  parts:  amnesia, 
analgesia,  unconsciousness,  immobility,muscle  relaxation  and  control  of 
autonomic and endocrine response to surgery.
Of these, opioids produce effects of analgesia, unconsciousness and 
control of autonomic and endocrine response to surgery. Butorphanol has 
been reported to produce anterograde amnesic effect.
Shivering: Post anaesthetic shivering,that is unrelated to hypothermia can be 
effectively abolished by certain  opioids like meperidine,  butorphanol  and 
tramadol.
CENTRAL NERVOUS SYSTEM:
Opioids generally produce modest decrease in cerebral metabolic rate 
(CMR). They cause decrease in cerebral blood flow when co administered 
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with nitrous oxide and a  cerebral  vasodilating anaesthetic.  Opioids affect 
intracranial  pressure  minimally,  but  may  cause  increase  in  intracranial 
pressure when compliance is compromised.
NON THERAPEUTIC DRUG EFFECTS:
While opioids have proved to be relatively safe drugs, management of 
side effects is critical to successful application in clinical practice.
RESPIRATORY EFFECTS:
Opioids  decrease  resting  minute  ventilation  and  tidal  volume. 
Respiratory rate may be decreased or normal, whereas µ agonists produce a 
dose related depression of breathing. Ventilatory response to hypoxia and 
hypercarbia  are  blunted.  Sufficient  doses  may  produce  apnoea,  but  the 
apnoeic conscious patient may breathe on command.
CARDIOVASCULAR EFFECTS:
The  action  of  opioids  on  cardiovascular  system  is  mostly  due  to 
histamine release.
Morphine  or  meperidine  which  cause  release  of  histamine  provide 
hypotension and tachycardia.
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Opioids  also  depress  contractility  of  isolated  heart  muscle,  but  at 
doses  greatly  in  excess  of  those  used  clinically.  An exception  to  this  is 
meperidine  which  produce  myocardial  depression  at  clinically  relevant 
concentrations. Morphine and fentany1 analogs decrease heart rate due to 
vagomimetic action. On the other hand, meperidine due to its anticholinergic 
properties increase heart rate.
RIGIDITY:
Opioid  induced  muscle  rigidity  occurs  usually  during  induction  of 
anaesthesia, especially with larger doses. This rigidity is central in origin, 
being mediated by µ receptors in brainstem medulla.
NEUROEXCITATORY EFFECTS:
Opioids  are  also  associated  with  tonic-clonic  movements  or 
myoclonus.
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GASTRO INTESTINAL EFFECTS:
These  effects  manifest  by  a  combination  of  central  and  peripheral 
actions. The effects observed are decrease in intestinal motility and increase 
in  the  tone  of  sphincter  of  Oddi.  Nausea  and  vomiting  is  a  commonly 
observed  effect  of  opioids  due  to  its  stimulation  of  receptors  at 
chemoreceptor trigger zone.
PRURITUS:
It is a common opioid-induced side effect, especially with neuraxial 
opioids.
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INTRATHECAL OPIOIDS
In the context of “Augmentation strategies” for spinal anaesthesia, the 
discovery  of  opioid  receptors  and  the  development  of  technique  of 
intrathecal opioid administration is one of the most significant advances in 
pain management in the last three decades. Plethora of studies have shown 
that spinal opioids can provide profound post operative analgesia with fewer 
neurological and systemic side effects than with systemic opioids. This is 
because neuraxial  opioids,  in  contrast  to  local  anaesthetics,  do not  cause 
sympathetic block, skeletal muscle weakness or lack of proprioception.
BRIEF HISTORY:
In  1900,  Matas  discovered  that  the  adverse  effects  of  intrathecally 
administered cocaine could be mitigated with the addition of morphine. He 
used  1.5mg  morphine  intrathecally  to  reduce  the  central  nervous  system 
effects of  cocaine.
In 1901, a Japanese anesthesiologist Otojiro Kitagawa, used 10mg of 
morphine with local anaesthetic eucaine intrathecally for cancer pain relief.
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With the discovery of opioid receptors in the spinal cord, intrathecal 
opioid administration quickly spread to perioperative care in a wide array of 
surgical procedures.
PHARMACODYNAMICS:
The exact mechanism of local anaesthetic-opioid interaction remains 
unknown despite detailed characterization of opioid receptor system at the 
cellular and molecular level.
When administered alone,spinal opioids selectively modulate C and A 
fibres with minimal  impact  on dorsal  root  axons.  Somatosensory  evoked 
potentials remain intact with respect to nerve conduction block. None of the 
opioids exhibit local anaesthetic property except possibly meperidine.
Local anaesthetics potentiate the antinociceptive effect of morphine, 
without an enhancement in motor block. Transient change in temperature 
perception  has  been  observed  with  spinal  meperidine,  fentanyl  and 
sufentanil.
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The  dorsal  root  entry  zone  is  speculated  to  be  active  site  for 
conduction block 
for spinal opioids. The hormonal milieu (pregnancy) also  contributes  to 
drug  effectiveness.  Spinal  progesterone  has  been  found  to  potentiate  the 
analgesic effects of spinal sufentanil in rats.
PHARMACO KINETICS:
It is beleived that hydrophilic opioids remain unbound in the CSF for 
a long time and hence to move rostrally in the CSF, thereby resulting in 
delayed respiratory depression.(eg) morphine.
In contrast lipophilic opioids do not move rostrally in CSF, but move 
more rapidly than hydrophilic opioids from CSF to spinal cord. But recently, 
studies have shown that even lipophilic opioids do not remain localized near 
their site of injection and they may rapidly move from lumbar intrathecal 
injection sites to cervical and brain stem levels via CSF.
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ONSET OF ACTION:
Lipophilic opioids spread more rapidly from the CSF into the spinal 
cord. Hence they have faster onset of action (eg.fentanyl) than hydrophilic 
opioids. The delayed onset of action of morphine, a hydrophilic opioid may 
in fact limit its utility as an intra operative adjuant.
ANALGESIC MECHANISMS:
The effects of intrathecally administered opioids are determined by 
the pharmacodynamics and pharmacokinetics of each individual drug. The 
dorsal  horn of the  spinal  cord is richly populated with opioid receptors. 
Majority of these are localized within substantia gelatinosa. Upon receptor 
activation, a G protein mediated effect result in inhibition of adenyl cyclase 
and  inward  flux  of  potassium.  This  flux  results  in  membrane 
hyperpolarization  and  decrease  in  neural  excitability  (anti  nociceptive 
effect). Opioids may act at synapses in spinal cord either presynaptically or 
postsynaptically.
µ receptor activation results in the presynaptic inhibition of substance 
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P release, a compound that would otherwise result in the activation of an 
integrated pain signal.
All clinically useful intrathecal opioids are strong µ receptor agonists 
within  the  dorsal  horn.  Their  supra  spinal  and  spinal  effects  act 
synergistically to blunt somatic as well as visceral pain. But analgesic effect 
is more specific for visceral pain. Analgesia of neuraxial opioids is also dose 
related.
DURATION OF ACTION:
The  duration  of  analgesic  action  will  depend  upon  the 
efficacy,lipophilicity,  receptor  affinity  and  the  dose  of  the  drug 
administered. Less lipid soluble drugs (eg morphine) will remain in the CSF 
for a longer time and hence will produce longer duration of analgesia than a 
highly lipophilic opioid like fentanyl.
High lipophilicity favours more rapid removal of the drugs from the 
receptor site into the blood stem,which limits the duration of action, only 
exception to this being buprenorphine.
POTENCY:
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H.J.MCQuay et al in 1989 published that the intrathecal potency is 
defined as the amount of drug required to produce a particular degree of 
receptor occupancy. It is inversely related to their lipid solubility and related 
directly to the affinity of the drug for the receptor. The inverse correlation 
between intrathecal potency and lipophilicity may be due to the nonspecific 
binding of highly lipophilic agents to the lipid rich fibres capping the dorsal 
horn, limiting their access to the receptors. Highly soluble opioid, pethidine, 
is  least  potent  and  has  to  be  used  in  systemic  does  for  intrathecal 
administration.
SIDE EFFECTS:
Opioids injected into the lumbar CSF may spread passively cephalad 
by diffusion and concentration gradient effect,aided by arterial pulsation and 
respiratory movements over a time course of 6-8 hours. They may reach the 
vicinity of the cisterna magnum and brain tissue of fourth ventricle.  This 
explains the occurrence of nausea, vomiting and respiratory depression after 
intrathecal administration.
Incidence  of  side  effects  is  dose  related  and  larger  doses  are  clearly 
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associated with higher incidence of side effects.
NAUSEA AND VOMITING:
Opioids commonly produce nausea and vomiting. The vomiting center 
in medulla receives inputs from many centers including the chemoreceptor 
trigger  zone,  which  contain  opioid  receptors  among  others  that  promote 
vomiting. But it  has been observed by Dahlgren et  al  that spinal  opioids 
administred along with local anaesthetics in spinal anaesthesia for cesarean 
sections decreased the requirement of intraoperative antiemetic medication.
Cooper et al reported a significant reduction in intraoperative nausea 
with the addition of  spinal  fentanyl  to  a  spinal  anaesthetic  for  cesaerean 
delivery. The effects are due to the dense sensory blockade achieved by the 
addition of opioids to local anaesthetics in spinal anaesthesia.
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PRURITUS:
It  is  a  peculiar  and  the  most  common  side  effect  with  neuraxial 
opioids. It is not confined to the segmental area of analgesia, but may be 
generalized or localized to the face, neck or upper thorax. Pruritis is usually 
very mild, servere pruritis occurring in about 1% patients Pruritis is more 
likely to occur in obstetric patients, perhaps due to interaction of estrogen 
with opioid receptors.
Though opioids may release histamine from mast cells, this is not the 
mechanism for pruritis. Pruritis may be due to a generalized modulation of 
cutaneous  sensation  or  in  the case  of  neuraxial  opioids,  due to  cephalad 
migration of the opioid in the CSF and subsequent interaction with opioid 
receptors in the trigeminal nucleus. Pruritus may or may not be dose related.
URINARY RETENTION:
This is usually encountered with hydrophilic spinal opioids. Urinary 
retention  is  most  likely  due  to  the  interaction  of  opioids  with  opioid 
receptors  in  sacral  spinal  cord.  This  promotes  inhibition  of  sacral 
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parasympathetic  nervous  systems  outflow  causing  detrusor  muscle 
relaxation and an increase in maximal bladder capacity. There is  also an 
increase  in  vesical  sphincter  tone.  All  these  factors  result  in  urinary 
retention. This effect is usually not dose related.
RESPIRATORY DEPRESSION:
This  is  a  major  problem,  limiting  the  use  of  spinal  opioids. 
Respiratory depression may occur early or late. Early respiratory depression 
is usually mild, occurs due to vascular uptake of drugs and occurs within one 
hour with morphine and within minutes with lipophilic opioids.
Late respiratory depression is more problematic and occurs 4-18 hours 
following intrathecal administration. This is due to the cephalad spread of 
drug in the CSF. Highly lipophilic opioids dissolve readily in neural tissue 
(segmental  localization),  thus  limiting  the  drug  available  for  cephalad 
spread.  Hence,  lipophilic  opioids  are  considered  safe  with  regard  to  late 
onset respiratory depression.
Factors  which  predispose  to  development  of  respiratory  depression 
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after intrathecal opioids are advanced age, high risk patients, larger dose of 
opioids, use of hydrophilic opioids, intrathecal administration as compared 
with epidural , concominant use of parenteral opioids or sedatives or both, 
opioid sensitive patients and thoracic epidural administration.
Obstetric patients are at lesser risk for ventilatory depression, perhaps 
because of the increased stimulation of ventilation by progesterone.
SEDATION:
This effect is dose related. Whenever sedation occurs, depression of 
ventilation should also be considered.
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CENTRAL NERVOUS SYSTEM EXCITATION:
Tonic skeletal  muscle  rigidity  resembling seizure  activity  is  a  well 
known  side  effect  of  intravenous  opioids,  but  is  rarely  observed  with 
neuraxial  opioids.  Myoclonic  activity  has  been  observed  after  neuraxial 
opioids. A possible explanation for this effect is the cephalad migration of 
the opioid in CSF and subsequent interaction with non opioid receptors in 
the brain stem or basal ganglia. In this regard, opioids may block, glycine 
and gamma amino butric acid mediated inhibition.
ANTAGONISM:
Systemically administered naloxone can antagonize all the side effects 
of spinal  opioids including repiratory depression.  Repeated doses may be 
required  to  maintain  adequate  ventilation.  Prophylactic  administration  of 
naloxone has also
been recommended by some to prevent pruritus, nausea, vomiting and other 
side effects. Analgesic effect of intra-thecal opioid is usually not affected  by 
naloxone.
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MERITS AND DEMERITS OF SPINAL OPIOIDS:
MERITS:
- Greater success rate of spinal anaesthesia
- Faster onset of surgical block than local anaesthetic alone
- Improved  intra  operative  analgesia  (enhanced  sensory  block 
without increased 
motor block)
- Reduction in the dose of local  anaesthetics  with faster  recovery 
from spinal 
anaesthesia
- Post operative analgesia beyond duration of local anaesthetic block
- Less nausea and vomiting
DEMERITS:
- Frequent pruritus
- Sedation (less with lipophilic opioids)
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- Rare respiratory depression (especially late onset)
- Rare urinary retention (more with morphine)
- Nausea,  vomiting,  somnolemce  and early  respiratory  depression 
due to vascular uptake of opioids. These are dose related.
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PHAMACOLOGY OF FENTANYL
Fentanyl  is  a  phenyl  piperidine derivative,  synthetic  opioid agonist 
that is structurally related to meperidine. As an analgesic fentanyl is 75 to 
125 times more potent that morphine.
PHARMACODYNAMICS:
A single dose of fentanyl administered intravenously has a more rapid 
onset  and  shorter  duration  of  action  than  morphine.  The  effect  site 
equilibrium time is 6.4 minutes. Rapid onset is due to its high lipophilicity 
and shorter duration of action is due to its rapid redistribution to inactive 
sites  such as  fat  and skeletal  muscles.  It  is  estimated that  75% of initial 
fentanyl dose is undergoing first-pass pulmonary uptake. When fentanyl is 
administered as continuous infusion, progressive saturation of these inactive 
tissue sites occur. As a result, the plasma concentration of fentanyl does not 
decrease  rapidly.  So  the  duration  of  analgesia,  as  well  as  depression  of 
ventilation, may be prolonged.
PHARAMACOKINETICS:
Fentanyl is  extensively metabolized by N-demethylation,  producing 
nor- fentanyl, which is structurally similar to normeperidine. Nor fentanyl is 
excreted by the kidneys and can be detected in the urine for 72 hours after 
intravenous dose of fentanyl. Even though fentanyl has a short duration of 
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action, its elimination half life is longer than that for morphine. This is infact 
due to  a  larger  volume of  distribution of  fentanyl.  The larger  volume of 
distribution is due to its greater lipid solubility and then more rapid passage 
of  drug into tissues compared with less  lipophilic  morphine.  The plasma 
concentrations of fentanyl are maintained by slow reuptake from inactive 
tissue sites, which account for its persistent effect.
CONTEXT SENSITIVE HALF TIME:
As the duration of continuous infusion of fentanyl increases beyond 
about 2 hours, the context sensitive half-time of this opioid becomes greater 
than  sufentanil.  This  reflects  the  saturation  of  inactive  tissue  sites  with 
fentanyl during prolonged infusions and return of the opioid from peripheral 
compartments to the plasma. This tissue reservoir of fentanyl replaces the 
fentanyl eliminated by hepatic metabolism so as to slow the rate of decrease 
in the plasma concentration of fentanyl when the infusion is stopped.
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DURING CARDIO PULMONARY BYPASS:
All  opioids  show  a  decrease  in  plasma  concentration  with  the 
initiation of cardio pulmonary bypass. The degree of this decrease is greater 
with fentanyl  because a significant  proportion of  the drug adheres to the 
surface of the cardiopulmonary bypass circuit. Sufentanil and alfentanil may 
provide  a  stable  plasma  concentration  during  cardio  pulmonary  bypass. 
Elimination of fentanyl and alfentanil  are prolonged by cardio pulmonary 
bypass.
CLINICAL USES:
Low  dose  of  fentanyl,1-2mcg/kg,  is  injected  to  provide 
analgesia.Moderate  dose  of  fentanyl,  2-20mcg/kg,  is  administered  as  an 
adjuvant  to  inhaled  anaesthetics  to  blunt  the  circulatory  responses  to  (a) 
direct laryngoscopic intubation (b) sudden change in the level of surgical 
stimulation.  Timing  of  fentanyl  administration  to  blunt  these  responses 
should consider the effect-site equilibration time.
Larger  doses  of  fentanyl,  50  -150mcg/kg have  been used  alone  to 
produce  surgical  anaesthesia.  The  advantage  of  larger  and  sole  fentanyl 
60
administration are (a) lack of myocardial depressant effect, (b) absence of 
histamine  release,  (c)  suppression  of  the  stress  responses  to  surgery. 
Disadvantage include (a)  post  operative depression of  ventilation and (b) 
possible patient awareness.
Fentanyl may be administered as a oral transmucosal preparation in a 
delivery device designed to deliver 5-20mcg/kg of fentanyl. In children aged 
2  to  8  years,  the  preoperative  administration  of  transmucosal  fentanyl 
15-20mcg/kg  45  minutes  before  the  induction  of  anaesthesia,  reliably 
induces  preoperative  sedation  and  facilitates  induction  of  inhalation 
anaesthesia. But there is more chance of post operative nausea and vomiting 
in these patients.
Transdermal fentanyl preparation delivering 75 to 100 mcg/hour result 
in peak plasma fentanyl concentration for about 18 hours that tend to remain 
stable during the 
presence of the patch, followed by decelerating  plasma concentration for 
several  hours  after  removal  of  the  delivery  system,  reflecting  continued 
absorption from the cutaneous depot.
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SIDE EFFECTS:
RESPIRATORY EFFECTS:
Persistent  or  recurrent  depression  of  ventilation  is  a  potential  post 
operative problem. There are two theories for  secondary peaks in plasma 
concentration of fentanyl.
One  is  due  to  sequestration  of  fentanyl  in  acidic  gastric  fluid.  This 
sequestered fentanyl could then be absorbed from the more alkaline small 
intestine back into the circulation to increase the plasma concentration of 
opioid  and  cause  depression  of  ventilation  to  recur.  Second  is  due  to 
washout of opioid from the lungs as ventilation perfusion relationships are 
reestablished in the postoperative period.
CARDIOVASCULAR EFFECTS:
Carotid baroreceptor reflex control of heart rate is markedly depressed 
by fentanyl. Bradycardia is more prominent with fentanyl and may lead to 
occasional decreases in blood pressure and cardiac output.
62
CENTRAL NERVOUS SYSTEM EFFECT:
           Seizure activity has been described to follow rapid intravenous 
administration of fentanyl, sufentanil and alfentanil. In the absence of EEG, 
it  is  difficult  to  distinguish  opioid-induced  skeletal  muscle  rigidity  or 
myoclonus from seizure acitivity. Opioids may produce a clinical picture of 
seizure activity in the absence of EEG changes.
Administration of fentanyl and sufentanil to head injury patients has 
been  associated  with  modest  increase  in  intracranial  pressure  despite 
maintenance  of  an  unchanged  PaCO2.  These  increases  in  intracranial 
pressure are typically accompanied by decrease in mean arterial pressure and 
cerebral perfusion pressure.
DRUG INTERACTIONS:
Analgesic concentrations of fentanyl greatly potentiate the effects of 
midazolam and decreases the dose requirements of propofol.  The opioid- 
benzodiazepine  combination  displays  marked  synergism  with  respect  to 
hypnosis and depression of ventilation.
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PHARMACOLOGY OF MIDAZOLAM
Midazolam is a water soluble imidobenzodiazepine. Benzodiazepines 
were introduced in early 1960s. Diazepam, the most popular drug of this 
group for the past 2 decades, is water insoluble, has a prolonged effect and is 
painful  during  injection.  The  unique  chemical  structure  of  midazolam 
confers a number of physiochemical properties that distinguish it from other 
benzodiazepines. This drug was synthesized in 1976 by Tryer and walser.
CHEMISTRY:
Benzodiazepines are so called because they consist of a benzene ring 
fused  with  a  seven  member  diazepine  ring.  Various  modification  in  the 
structure of the ring systems have yielded compounds with similar activities.
Midazolam with molecular weight of 362, has a fused imidazole that 
is different from classic benzodiazepines. The imidazole ring accounts for 
the basicity, stability of an aqueous solution and rapid metabolism. The ring 
exhibits a PH dependent ring opening phenomenon. The ring opens at pH 
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less than 4 making the drug soluble in aqueous solution. Once midazolam 
enters  the  body,  the  pH  changes  to  7.5  and  drug  assumes  closed  ring 
structure  and becomes  highly  lipid  soluble.  Midazolam is  the  most  lipid 
soluble benzodiazepine.
PHARMACOKINETICS:
Midazolam is  rapidly absored from gastro intestinal  tract,  but  only 
50% of the orally given drug enter the circulation, as substantial portion is 
metabolized during the first hepatic flow. Thus the oral dose is twice as high 
as intravenous dose.
Peak  plasma  concentrations  are  seen  within  an  hour  of  ingestion. 
When  given  intramuscularly,  the  absorption  is  more  predictable  than 
diazepam. Being highly fat soluble it crosses blood brain barrier more easily 
than diazepam, to gain access to the receptors. It has a more rapid onset of 
action. After intravenous administration of midazolam to healthy adults, the 
disappearance  of  midazolam  from  the  plasma  proceeds  in  two  distinct 
phases.  The  initial  phase  of  rapid  disappearance  is  due   principally  to 
distribution of the drug while the final and slower phases of disappearance is 
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attributable  mainly  to  biotransformation.  The  volume  of  distribution 
averages between 1 and 2.5 1/kg.  Midazolam is tightly bound to plasma 
protein.  After  distribution  equilibrium is  reached.Its  elimination  half-life 
varies  from 1  to  4  hours.  Midazolam is  metabolized  mainly  by  hepatic 
microsomal oxidative mechanism, by a process of hydroxylation. The fused 
imidazole ring is oxidized very rapidly to both 1 and 4 hydroxy midazolam. 
Both these products are conjugated to glucuronides and are excreted in the 
urine. The metabolites have less than 1% activity of the parent drug.
FACTORS AFFECTING PHARMACOKINETICS:
1. Old age-Elimination half-life is increased and clearance is delayed.
2. Obesity- The volume of distribution is increased. This increases 
the  elimination  half-life,  but  there  is  no  change  in  the  total 
metabolic clearance.
3. Renal  insufficiency-As  less  than  1%  of  midazolam  is  cleared 
through the kidney, there is minimal alteration of its clearance in 
patients with renal insufficiency. The free fraction of midazolam in 
the plasma is increased due to decreased plasma binding.
4. Pregnancy  –  Midazolam  crosses  the  placental  barrier,  but  the 
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placental transmission as judged by foetal – maternal plasma ratio 
in animals.It is less for midazolam than for diazenpam.
5. Gender – males are more susceptible to midazolam than female 
patients.
MECHANISM AND SITE OF ACTION:
An important inhibitory neurotransmitter in the brain is gamma amino 
butric acid (GABA), while glycine is the major inhibitory neurotransmitter 
in the spinal cord and brainstem. The benzodiazepines augment GABA thus 
producing sedation and anticonvulsant activity, while anxiolysis and muscle 
relaxation appear to be due to glycine mimetic effects in the spinal cord and 
brainstem.
Among the benzodiazepines midazolam has greatest affinity for the 
receptors,  but  dissociate  faster  from the receptor,  thus accounting for  the 
rapid onset and shorter duration of action. Given intrathecally or epidurally, 
midazolam produces analgesia which is GABA mediated. Muscle relaxation 
produced  by  midazolam is  due  to  potentiation  of  glycine  action  on  the 
anterior horn cells.
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PHARMACODYNAMICS:
CENTRAL NERVOUS SYSTEM:
Midazolam has anxiolytic, hypnotic, anticonvulsant, muscle relaxant 
and anterograde amnestic properties. It decreases the cerebral metabolic rate 
and  cerebral  blood  flow.  Cerebral  perfusion  pressure  decrease  as  the 
systemic pressure falls more than the intracranial pressure. Given in doses of 
0.25mg/kg it does not alter intracranial tension and therefore it can be used 
for neurosurgical procedures. Emergence from induction is more rapid than 
diazepam,  but  not  so,  when  compared  with  thiopentone  Midazolam 
decreases the anaesthetic requirement of inhalational agents.
CARDIOVASCULAR SYSTEM:
Midazolam  decreases  the  myocardial  contractility  and  systemic 
vascular  resistance and causes vasodilatation,  thus causing fall  in arterial 
pressure. The fall  in blood pressure is  similar to that caused by hypnotic 
doses  of  thiopentone,greater  than  that  caused  by  equipotent  doses  of 
diazepam and less than that caused by propofol. It increases the heart rate. 
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Midazolam does  not  abolish  the  stress  response  to  intubalion,   but   the 
increase  in  heart  rate  and  blood  pressure  are less  than  seen  with 
diazepam.  Midazolam  dose  not  alter  coronary  vascular  resistance  and 
dose  not  cause  coronary  steal  phenomenon.
RESPIRATORY SYSTEM:
           Midazolam  causes  dose  dependent  depression of  ventilation.  In 
doses  used   for   premedication   or   sedation,   it   dose   not   alter   the 
carbondioxide   response,   but   in   doses   above   0.2mg/kg   it   causes 
respiratory  depression. Apnoea   produced  by  midazolam  is  dose  related 
and  is more  common  in patients  premedicated  with  opioids, in chronic 
obstructive  pulmonary  disorder  patients,  and  following faster   injection 
of  the drug,  Their  respiratory  depression  is reversed  by  flumazenil  but 
not by  naloxone.  
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INTRATHECAL MIDAZOLAM: 
          Spinal  midazolam  produces analgesia  by  binding  to  specific 
benzodiazepine   receptors  in  the  dorsal   horn  of  the  spinal   cord. 
Musclerelaxation  is  by  potentiating   the effect  of  glycine  which  is  an 
inhibitory  neurotransmitter  to  the  anterior  horn  cells.
IN  VITROCHANGES  IN  TRANSPARENCY  AND  PH    OF  CSF 
CAUSED BY ADDING MIDAZOLAM:
CSF  PH  was  decreased  below  7.0  by  adding  more  than  3mg  of 
midazolam., CSF transparency was decreased by adding more than 7mg of 
midazolam. Midazolam in saline neither decreased the pH nor reduced the 
transparency. The pharmacokinetics of intrathecal midazolam depend on the 
molecular weight, lipid solubility and the systemic vascular absorbtion.
ANTAGONIST OF MIDAZOLAM:
Flumazenil  is  an  imidazo  benzodiazepine,  with  specific 
benzodiazepine antagonist activity. Flumazenil  binds with high affinity to 
specific sites when it competitively antagonizes the binding and allosteric 
effects of benzodiazepine. The intravenous administration of 0.3 to 1mg of 
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flumazenil is usually sufficient to abolish the effects of therapeutic doses of 
benzodiazepines  within  1to2  minutes.  Additional  doses  may  be  required 
after 1 to 2 hours.
USES OF MIDAZOLAM:
1. Premedication dose is 0.05 mg/kg to 0.1 mg/kg intramuscularly or 
10-15 mg per oral. I has predictable absorption after intramuscular 
injection. It produces amnesia, anxiolysis and sedation.
2. Intravenous sedation dose is 0.05 mg/kg to 0.1 mg/kg.  Sedation 
occurs    
      without loss of air way reflexes, causes no vomiting and post 
operative  
     drowsiness is less.
3. Induction dose is 0.15mg/kg to 0.3mg/kg and induction is faster 
than with 
     diazepam.
4. DAY CARE SURGERY: Because of rapid onset and brief half-
life  midazolam is a  suitable drug.  But patients  should not  drive 
vehicles for at least eight hours as midazolam affects psychomotor 
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function and postoperative instructions should  be written down.
5. Midazolam can be used in treatment of emergence phenomenon
DRUG INTERACTIONS:
Erythromycin, clarithromycin and flucanozole increase the effect of 
midazolam due to inhibition of cytochrome P450 III A enzyme. H2  receptor 
antagonist  also  inhibit  cytochrome  P450  III  A  enzyme.  Asprin  and 
probenecid  increase  the  effect  by  competing  for  protein  binding  site. 
Phenytoin, rifampicin and xanthines decrease the efficacy of midazolam due 
to increased metabolism by inducing cytochrome P450.
SIDE EFFECTS:
Nausea  and vomiting  are  minimal.  Incidence  of  hiccough is  5.6%, 
cough1.5%.
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REVIEW OF LITERATURE
1. A  comparative  study  of  intra-thecal  fentanyl  and  midazolam  for 
prevention of nausea-vomiting during caesarean delivery under spinal 
anaesthesia  was  done  by  Dr.Pallab  Rudra,Dept.  of 
Anaesthesiology,Calcutta  National  Medical  College  and 
Hospital,Kolkatta. They concluded that co-administration of fentanyl 
12.5 μg or midazolam 2 mg in the sub-arachnoid space avoid intra-
operative discomfort during peritoneal traction and exteriorization of 
the  uterus  and thereby  reduce  the  incidence  of  intra-operative  and 
early post-delivery nausea-vomiting in caesarean section under spinal 
anaesthesia with 0.5% hyperbaric bupivacaine. The study is published 
in Indian Journal of Anaesthesia,Dec 2004,Vol.48.
2.  Dahlgren  ,Gunnar  et  al  1997,  observed  that  spinal  opioids 
administered along with local  anaesthetics in spinal  anaesthesia for 
caesarean section decreased the requirement of intra-operative anti-
emetic medication.
3.  Cooper et al reported a significant reduction in intra-operative nausea 
with  the  addition  of  fentanyl  to  spinal  anaesthetic  for  caesarean 
delivery. The effects are due to the dense sensory blockade achieved 
by the addition of opioids to local anaesthetics in spinal anaesthesia.
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4. Palmer CM et al in 1995 conducted a study where 15 μg of fentanyl 
was  added  as  a  sole  adjuvant  to  hyperbaric  lidocaine  in  spinal 
anaesthesia  in  parturients  undergoing  caesarean  delivery  and 
concluded  that  the  addition  of  fentanyl  increases  the  duration  of 
effective analgesia by approximately 30min.& provides a protective 
effect regarding nausea & vomiting in the peri-operative period. 
5. Manullang  T.R,  Viscome  CM,  Pace  HL observed  that  intra-thecal 
fentanyl is superior to intra-venous ondansetron for the prevention of 
perioperative  nausea  during  caesarean  delivery  with  spinal 
anaesthesia.  This  study  is  published  in  Anaesth  Analg 
2000;90:1162-66.
6. Sen A,Rudra A observed that intra-thecal midazolam prevents nausea-
vomiting during caesarean delivery with spinal anaesthesia. The study 
is  published  in  Journal  of  Anaesthesia  and  Clinical  Pharmacology 
2002;18:21-25.
7. Mac  Donald  R.L.  and  Young  A.B.  in  1981  demonstrated  GABA 
mediated inhibition of the spinal cord neurons in vivo and in primary 
dissociated cell culture.
8. In  1990 Wal  dovel  H.J.  and co-workers  conducted  a  study  on the 
regional  cellular  and  sub-cellular  distribution  of  GABA  and 
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benzodiazepine  receptors.  The  highest  density  of  GABA  and 
benzodiazepine receptors are localized as a dense band within lamina 
2 of the dorsal horn with moderately high concentration in lamina 1 
and 3.
9. In  1994,  Australian  Society  for  Clinical  Experimental 
Pharmacologists and Toxicologists conducted a study on the GABA 
receptors  and demonstrated the presence  of  Non-A,  Non-B GABA 
receptors.  These  were  known  as  Novel  receptors.  These  are  the 
receptor sites where intra-thecally administered midazolam act.
10. In 1996, Valentine J.M and co-workers compared the postoperative 
analgesia provided by intrathecal bupivacaine, intrathecal bupivacaine 
and  morphine,  intrathecal  bupivacaine  and  midazolam  in  patients 
undergoing caesarean sections.The use of patient controlled analgesia 
was greater  with plain  bupivacaine group and patients  given intra-
thecal morphine had pruritus. Intrathecal midazolam provided useful 
analgesia without side effects.
11. Clinical  Journal  for  Pain,1996  March,  states  that  epidural  and 
intrathecal midazolam is more effective against somatic pain.
12. A study was conducted in Dept.of Anaesthesiology,Samsung Medical 
Centre,  Korea  by  M.H.Kim and  Y.M.Lee  which  was  published  in 
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British  Journal  of  Anaesthesia  2001,  about  the  potentiation  of 
analgesic effect of intrathecal bupivacaine by intrathecal midazolam. 
These groups of patients were randomlt allocated and control group 
received 5 mg of bupivacaine and 0.2 ml of 0.9% saline, second group 
received  5  mg  of  bupivacaine  and  2  mag  of  midazolam.  They 
concluded that time to first analgesia was significantly greater in the 
midazolam group than in the placebo and significantly less in patients 
in second group than in the third.
13. Works  of  Matan  in  1900  combining  morphine  with  intrathecal 
cocaine appears to be one among the first attempt to enhance spinal 
anaesthesia with spinal opioids.
In 1901, two independent reports, one by a Japanese anaesthesiologist 
and  the  second  by  a  Romanian  Surgeon,  have  been  published 
mentioning the efficacy of opioids when used in sub-arachnoid block.
In 1965, Gate Control theory of pain proposed by Melzack and Wall 
focused  on  the  importance  of  dorsal  horn  of  spinal  cord  in  the 
modulation of pain.
In 1973 Pert  and Snyder  identified  specific  opiate  receptors  in  the 
substantia gelatinosa of dorsal horn of spinal cord.
In 1976, Yaksh and Reddy suggested that intrathecal opioids act at the 
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presynaptic receptors in the substantia gelatinosa and block the release 
of neuro-transmitters. This study was undertaken in rats.
In 1984, Huand H.J. Ishimain T,Yambe studied the use of intrathecal 
morphine for postoperative pain relief.
14.  A  study  of  effect  of  intra-thecal  fentanyl  added  to  hyperbaric 
bupivacaine  for  caesarean  section  was  conducted  at  Dept.of 
Anaesthesiology,  Tokyo  University  School  of  Medicine,Tokyo.  24 
patients posted for elective caesarean section were allotted to receive 
either 15 μg of fentanyl or 0.9% normal saline added to 2 ml of 0.5% 
hyperbaric  bupivacaine  intra-thecally  in  right  lateral  decubitus 
position.  They  concluded  that  addition  of  fentanyl  to  intrathecal 
bupivacaine  in  parturients  undergoing  caesarean  section  improved 
quality of anaesthesia without producing side effects.
15. A study was published in Indian Journal of Anaesthesia 2002 about 
intrathecal  fentanyl  added  to  hyperbaric  bupivacaine  improving 
analgesia during caesarean section and early postoperative period. It 
was conducted by Dr.Biswas, Dr. Nath & Dr.Bhattacharjee.
They randomly allotted 40 parturients coming for elective caesarean 
section into two groups. Group 1 received 2 ml of 0.5% bupivacaine 
with  0.25  ml  of  0.9%  saline.  Group  2  received  2  ml  of  0.5% 
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bupivacaine with 12.5μg of fentanyl. They concluded  that 12.5 μg of 
fentanyl  added to  intra-thecal  bupivacaine could markedly  improve 
intra-operative anaesthesia  and significantly  reduce the demand for 
post-operative analgesia with good maternal satisfaction and fetal well 
being.
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MATERIALS AND METHODS
              The study was conducted in 100 patients posted for elective and 
emergency  surgeries  after  getting  approval  of  ethical  committee  of 
Department of Anaesthesiology, Government Rajaji Hospital and Madurai 
Medical College,Madurai. Informed consent was obtained after explaining 
the procedure.
INCLUSION CRITERIA:
-Adult patients aged 25+/-5 yrs.
-ASA physical status 1&2.
-Caesarean sections.
-Ht:155+/-5 cm  Wt: 55+/-5 kgs
EXCLUSION CRITERIA:
-H/o hyperemesis gravidarum
-Contra-indication to regional anaesthesia.
-Patients with GI disorders like peptic ulcer,foetal prematurity (36 wks)
-Those who have received anti-emetics 24 hrs. before surgery.
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-Those who are administered methyl-ergometrine& Prostaglandin f2α intra-
operatively  for uterine contraction.
Patients are grouped into three groups Group F,  Group M and Group B. 
Group F and Group M have 40 patients each and Group B has 20 patients. 
Group F
0.5% Bupivacaine 1.6 cc + 0.25 ml of fentanyl (12.5μg)
Group M
0.5% Bupivacaine 1.6 cc+ 0.25 ml of midazolam (1.25 mg)
Group B
0.5% Bupivacaine 1.6cc+ 0.25 ml of normal saline.
Total volume of solution in all the three groups is 1.85 ml.
PROCEDURE
Patients were explained about the procedure.
Base-line pulse rate, blood pressure, respiratory rate were recorded.
Intra-venous line was secured with 18 G Cannula.  Pre-loading was done 
with 15-20 ml /kg of crystalloid solution. The following emergency drugs 
and equipments were kept ready.
-Boyle’s anaesthetic machine with oxygen cylinder.
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-Laryngoscope with varied blades
-Oro-pharyngeal airway.
-Endo-tracheal tubes.
-Suction apparatus
-Drugs  like  atropine,  adrenaline,  ephedrine,dexamethasone,deriphylline, 
dopamine and naloxone.
    Patients were put on right lateral position. Under strict aseptic precautions 
sub-arachnoid block was performed using 23G Quincke Babcock’s needle in 
L3-4 interspaces. After ensuring free flow of CSF the drug was injected as 
per the group assigned. After injecting the drug patients were turned supine.
RECORDING DATA:
The following were recorded
1 Time of institution of subarachnoid block
2 Maximum level  of  sensory  block  achieved  (which  is  tested  by 
pinprick)
3 Time of onset of surgery
4 Pulse rate, blood pressure, respiratory rate and oxygen saturation 
were monitored every 5 minutes for the first 15 minutes, thereafter 
every 20 minutes for rest of the surgery and every half an hour in 
the post operative period.
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5 Hypotension was said to have occurred, if there was a fall in blood 
pressure  30%  from  the  baseline.  This  was  treated  with  100% 
oxygen  through  face  mask,  intravenous  fluids  and ephedrine  in 
titrated doses.
6 Respiratory depression is  said to  have occurred if  Spo2 falls  to 
<92% or the respiratory rate falls to <8. The condition is treated by 
O2supplementation via face mask.
7 Discomfort, if any experienced by the patient during surgery was 
recorded in  the  intraoperative  period  & degree  of  sedation  was 
scored .
SEDATION SCALE
i. Patient awake anxious and agitated
ii. Patient awake oriented and tranquil
iii. Patient asleep but responds to commands only
iv. Patient asleep but responds briskly to light glabellar tap 
or loud auditory stimuli.
v. Patient asleep but responds sluggish to light glabellar tap 
or loud auditory stimuli.
vi. Patient asleep with no response to stimuli.
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8 Occurrence of nausea/vomiting in the intra-operative & early post-
operative  period  was  noted.  Other  adverse  effects  like  rigors, 
respiratory depression were noted.The statistical significance was 
brought by student t test.
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OBSERVATION AND RESULTS
The following observations were made during the intra-operative period.
DEMOGRAPHIC DATA:  All the patients are matched for age, height and 
weight.
Age: 25+/- 5.
Height: 155+/-5 cm
Weight: 45+/-5 cm
HIGHEST DERMATOME LEVEL ACHEIVED
The maximum level of sensory block achieved was elicited with pinprick. 
The maximum level achieved in each group was:
Group B: 5% of patients had sensory block upto T4.
    
               20% of patients had sensory block upto T5.
               30% of  patients had sensory block upto T6.
                5% of  patients had sensory block upto T10.
              15% of patients had sensory block upto T7.
                5% of patients had sensory block upto T9.
Group F: 22% of patients had sensory block upto T4.
               58% of patients had sensory block upto T5.
               20% of patients had sensory block upto T6.
Group M: 13% of patients had sensory block upto T4.
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                 20% of patients had sensory block upto T5.
                 67% of patients had sensory block upto T6.
Using the Chi-square test, with a `p’ value of 0.00013, the values obtained 
are considered statistically significant. 
EMETIC EPISODES 
In Group F, 80% of patients had no nausea/retching or vomiting.
                   10% of patients had nausea.
                    5% of patients had both nausea& vomiting
                   5% of patients had only vomiting.
In Group M, none of the patients had vomiting.
In Group B, only 15% of patients had vomiting.
Hence, nausea & vomiting does’nt appear to be significantly present in any 
of the 
groups.
PAIN
In Group M,8% of patients had intra-operative pain. 
In Group B, 50% of patients had intra-operative pain.
In Group F, no patients complained of pain.
Those 8% patients in Group M complained of pain at the end of surgery 
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which was controlled by administering narcotics intra-venously. 
RIGORS
In Group F, 13% of patients had rigors intra-operatively
In Group M, 10% of patients had rigors intra-operatively
In Group B, none of them had rigors intra-operatively.
    Values in Group F& Group M are considered statistically significant with 
a  ‘p’  value  of  0.0201  &  0.0393  respectively   when  compared  with  the 
control group.
HYPOTENSION
In Group F, 25% of patients had intra-operative hypotension.
In Group M, 8% of patients had intra-operative hypotension.
In Group B, 5% of patients had intra-operative hypotension.
None  of  the  groups  had  values  which  are  considered  to  be  statistically 
significant.
RESPIRATORY DEPRESSION
In Group F, 30% of patients had respiratory depression.
In Group M, 13% of patients had respiratory depression.
Both the groups were found to have a statistically  significant  association 
with ‘p’ values of 0.0001 & 0.0201 in comparison with control.
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SEDATION
In Group F,20% of patients had sedation score of 1.
                  75% of patients had sedation score of 2.
                   5% of patients had sedation score of 3.
In Group M,8% of patients had sedation score of 1.
                   92% of patients had sedation score of 2.
None of the values appear to be statistically significant.
In Group B, all the patients had a sedation score of 1.
PRURITUS
In Group F, 15% of patients had pruritus;which settled on its own.
FOETAL OUTCOME
In none of the neonates, in all the 3 groups, Apgar scores were less than 6/10 
in the 1st min. & 8/10 in the 5th min.
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DISCUSSION
    Nausea  and  Vomiting   commonly  occur  during  caesarean  delivery 
performed  under  Spinal  anaesthesia,  and  is  frequently  related  to  intra-
operative hypotension, peritoneal traction and exteriorization of the uterus. 
These problems may be accompanied by visceral pain, that stimulate vagal 
afferents,  which  occurs  despite  apparently  adequate  dermatomal  sensory 
blockade.  Various  pharmacological   agents   have  been  used 
prophylactically,however,  either  undesirable  effects  or  cost  of  the  agents 
limited their routine use.
        Intrathecal lipophilic opioid,fentanyl and benzodiazepine,midazolam 
have been 
observed to provide improved intra and post-operative analgesia and thereby
decreasediscomfort  from  intra-operative  peritoneal  manipulations  which 
may initiate emetic episodes.(Ref: Miller’s TextBook of Anaesthesiology 6th 
edition, Wylie&Churchill TextBook of Anaesthesiology,7th edition).
       In our study, none of the three groups had statistically significant 
incidence of nausea& vomiting. This is in agreement with the observations 
of Dahlgren et al,  Biswas BN, Sen A.This is  also in agreement with the 
observations of Dr.Pallab Rudra& Dr.A.Rudra. The % of patients (20) in 
fentanyl group with emetic episodes was more than in the remaining two 
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groups.This is in contrast to the observations of Dr. Pallab Rudra & Dr.A. 
Rudra where nausea&vomiting was less in the fentanyl group than in the 
midazolam group.(↓to 25% with fentanyl whereas it is ↓to only 40% with 
midazolam).Among Group M & Group B,  15% in Group ‘B’ had  vomiting 
whereas  none  of  the  patients  in  Group  ‘M’  had  intra-operative 
nausea/vomiting.
              Hypotension was present in all the three groups , but not found to 
be  statistically  significant.  It  was  aggressively  treated  with  IV  fluids  & 
aliquots of IV ephedrine.
             Only 15% of patients in Group ‘F’ had pruritus,the low incidence 
being due to the highly lipophilic nature of the drug and the small dose used, 
which  limited  its  rostral  spread.This  is  similar  to  the  observations  of 
Dr.Pallab  Rudra,where  only  5%  of  the  patients  developed  pruritus.  It 
subsided on its own.
                   None of the neonates showed reduced Apgar score . Hence it is 
observed that the addition of either of the adjuvants (fentanyl or midazolam 
to Bupivacaine) does’nt have any influence on neonatal outcome.It would 
have been better if umbilical cord blood analysis for pH, pCO2 and base-
excess  were  assessed  to  find  out  any  subtle  insults  to  the  newborn. 
However,such provisions are not available at our institution.
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                  Dilution of a solution produce a difference in volume as well as 
the  baricity  of  the  solution.  A  very  dilute  solution  produces  differential 
blockade characterized by autonomic blockade, minimal sensory anaesthesia 
and  no  effect  on  motor  function.  (Ref:  North  American  Clinics  – 
Epidural&Spinal analgesia& anaesthesia-March 1992). This is responsible 
for the patchiness of blockade observed in the control group. The difference 
in  baricity  also  contributes  to  differing  dermatomal  levels  of  blockade 
observed in the control group. 
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CONCLUSION
            The incidence of nausea and vomiting is found to be considerably 
reduced when Fentanyl or  midazolam is  added to Bupivacaine for  spinal 
anaesthesia during caesarean section.
       Among the two agents, midazolam is found to be superior to fentanyl  in 
providing intra-operative  comfort  during  visceral  handling  and peritoneal 
traction.
     Adverse effects like pruritus, rigors, hypotension were not found to be 
statistically  significant  in  the study group of  patients  whereas respiratory 
depression was found to be statistically significant in both the groups when 
compared to control group.
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COMPARISON OF INTRATHECAL FENTANYL 
AND MIDAZOLAM
WITH INJ.BUPIVACAINE FOR PREVENTION OF
NAUSEA AND VOMITING DURING CAESAREAN DELIVERY
PROFORMA
NAME: AGE: IP.NO: HT: WT:
INVESTIGATIONS:
BLOOD GROUP:    Rh: Hb%:   BLOOD SUGAR: BLOOD 
UREA:
 SUB ARACHNOID BLOCK:  SPACE:L3-L4
TIME OF BLOCK: MAXIMUM LEVEL  OF 
BLOCK:
     ONSET OF SURGERY:
INDUCTION  –  DELIVERY  TIME:     mins.  SKIN  INCISION  – 
DELIVERY TIME:
UTERINE INCISION – DELIVERY:    mins. 
DURATION OF UTERUS EXTERIORISATION:   mins.
DURATION OF SURGERY:            mins.
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INTRA-OPERATIVE MONITORING:
TIME PULSE B.P SPO2 OTHERS
EMETIC EPISODES:   NAUSEA / VOMITING / RETCHING
RESCUE ANTI EMETIC: INJ.METACLOPROMIDE 10 Mg: YES / NO
OTHER SIDE EFFECTS: PRURITIS /  SHIVERING /  RESP.  RATE / 
SPO2
       SEDATION SCORE:
NEONATAL OUTCOME: APGAR SCORE: AT 1 min:          AT 5 min:
REMARKS 
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